Insulet (PODD) FY2025 10-K Risk Factors: 5 New, 9 Dropped

What the changes say

International sales reached 28% of 2025 revenue as Omnipod 5 launches expand, with greater exposure to foreign operations and tariffs.
Supply-chain concentration remains material, including China and Malaysia manufacturing and single-location inventories in Massachusetts and the Netherlands.
Growth is increasingly tied to Omnipod 5, international expansion, and entering the insulin-requiring type 2 diabetes market.
Leadership changes, AI regulation, reimbursement negotiations, and named competitors add more specific execution and commercial risks.

What changed since the prior 10-K

New

NewRisks Related to Our Business
If we fail to expand our relationships with intermediaries, our ability to grow our business may be materially and adversely affected
Dependence on intermediaries to market and distribute Omnipod products could delay adoption or reduce sales if they underperform.
NewRisks Related to our Intellectual Property
We may be unable to adequately protect our intellectual property rights, which could limit our ability to sell our products profitably, or at all, and cause us to incur additional costs
Challenged, stolen, invalidated, or counterfeit intellectual property could enable competing products, damage reputation, and increase enforcement costs.
NewRisks Related to Economic Conditions and Operating Internationally
The international nature of our business subjects us to additional business risks that may have an adverse effect on our financial condition or results of operations
International expansion, foreign suppliers, China manufacturing, and Malaysia operations expose Insulet to political, trade, tax, currency, and regulatory risks.
NewRisks Related to Economic Conditions and Operating Internationally
Expansion of U.S. tariffs could have a material adverse effect on our financial results
Expanded U.S. tariffs or removal of medical-device exemptions could raise supply-chain costs, restrict components, and reduce financial results.
NewRisks Related to Reliance on Third Parties and Business Continuity
Our inventory is produced and maintained in a limited number of locations, including one operated by a third party in China, and any loss could have a material adverse effect on our ability to manufacture and sell our products
Disruptions at China or Malaysia manufacturing sites or single-location inventories could interrupt Omnipod supply and increase costs.

Dropped

DroppedRisks Related to Our Business and Industry
If we fail to expand and maintain an effective sales force or successfully develop and maintain our relationships with intermediaries, our business, prospects, and brand may be materially and adversely affected
DroppedRisks Related to Competition, Product Development and Intellectual Property
As a result, we may not be able to compete effectively against these companies or their products, which may adversely impact our business
Expanding the direct sales force and domestic and international intermediary distribution relationships.
DroppedRisks Related to Competition, Product Development and Intellectual Property
We may be unable to adequately protect our intellectual property rights
DroppedRisks Related to Economic Conditions and Operating Internationally
Another global pandemic could adversely impact our business and financial condition
DroppedRisks Related to Economic Conditions and Operating Internationally
Our financial condition or results of operations may be adversely affected by international business risks
DroppedRisks Related to Supply Chain, Operations, and Drug Delivery
Our inventory is produced and maintained in a limited number of locations
DroppedRisks Related to Information Technology, Privacy and Security
The rapidly-changing technical and regulatory environment and our AI-related activities may have an adverse effect on our business
DroppedRisks Related to Our Debt
Conversion of any of our Convertible Senior Notes may dilute the ownership interest of existing stockholders or depress our stock price
Competition from insulin patch pumps, smart pens, and other diabetes treatments.
DroppedGeneral Risks
A material weakness in our internal control over financial reporting could result in material misstatements in our financial statements and cause us to fail to meet our reporting and financial obligations

Reworded

93% rewrittenRisks Related to Competition and Product Development
Our new product development initiatives may prove to be ineffective or not commercially successful
The risk now emphasizes failed customer-need anticipation, clinical trials, global approvals and reimbursement, cost-effective manufacturing, intellectual property, and AI regulation.
90% rewrittenRisks Related to Our Business
We currently rely on sales of our Omnipod product platform to generate most of our revenue
The wording now focuses on retaining and growing Omnipod customers rather than listing specific adoption, reimbursement, manufacturing, and quality threats.
Was: We currently rely on sales of our Omnipod product platform to generate nearly all our revenue
83% rewrittenRisks Related to Competition and Product Development
Our failure to compete effectively would negatively impact our revenue and results of operations
Competitor names were updated to Medtronic Diabetes, Tandem, and emerging Beta Bionics; the detailed MDI cost and resource comparison was shortened.
Was: Our failure to compete effectively would negatively impact our revenue
78% rewrittenRisks Related to Our Business
If we do not effectively manage our rapid growth, our business resources may become strained and we may not be able to deliver our products in a timely manner, which could adversely affect our results of operations
Growth drivers now explicitly include international expansion and insulin-requiring type 2 diabetes, with added risks around inventory and hiring capacity.
64% rewrittenRisks Related to Our Business
Our ability to grow our revenue depends in part on our retaining a high percentage of our customers
Customer-retention risks now specifically include perceived inadequate customer service and product performance issues, while removing unemployment and reimbursement references.
57% rewrittenGeneral Risks
Our success depends on our ability to attract, motivate, and retain key personnel
The risk now names 2025 CEO and CFO changes and potential disruption from integrating leadership and maintaining critical-function continuity.
56% rewrittenRisks Related to Economic Conditions and Operating Internationally
The continuing worldwide macroeconomic and geopolitical uncertainty as well as the impact of another global pandemic may adversely affect our business and prospects
The macroeconomic risk adds elections, political divisions, social concerns, reduced capital-market availability, and heightened geopolitical and geoeconomic instability.
Was: The continuing worldwide macroeconomic and geopolitical uncertainty as well as the impact of global pandemics may adversely affect our business and prospects
56% rewrittenRisks Related to Our Business
Failure to secure or retain adequate coverage or reimbursement for our products by third-party payors could adversely affect our business, revenue, financial condition, and results of operations
The reimbursement discussion now adds Medicare Part D coverage negotiations and removes detailed statements about pharmacy-channel limitations and existing coverage breadth.
Was: Failure to secure or retain adequate coverage or reimbursement for our products by third-party payors could adversely affect our business, financial condition, and results of operations
55% rewrittenRisks Related to Reliance on Third Parties and Business Continuity
Our manufacturing process is highly complex and subject to regulation; as demand for our products increase, we may experience manufacturing difficulties, including not effectively managing the start-up of new manufacturing lines or issues with our third-party contract manufacturer, which could harm our business
47% rewrittenRisks Related to Competition and Product Development
Future market or clinical studies may be unfavorable to our Omnipod products and their efficacy, which could hinder our sales efforts and have a material adverse effect on our business, results of operations, financial condition, and cash flows
37% rewrittenRisks Related to Our Business
Our non-insulin Drug Delivery product line faces challenges which, if not met, may impair its future success
36% rewrittenRisks Related to Information Technology (“IT”), Privacy and Security
We rely on the proper function, availability, and security of our products and IT systems; a successful cyber-attack or other breach or disruption of our products or these systems could have a material adverse effect on our business and results of operations
Was: We rely on the proper function, availability, and security of our product and information technology systems; a successful cyber-attack or other breach or disruption of our product or these systems could have a material adverse effect on our business and results of operations
33% rewrittenRisks Related to Government Regulation and Product Liability
If we or our contract manufacturer fail to comply with the FDA’s quality system regulations, the manufacturing and distribution of our devices could be interrupted, and our sales and operating results could suffer
Was: If we, our contract manufacturer or our component suppliers fail to comply with the FDA’s quality system regulations, the manufacturing and distribution of our devices could be interrupted, and our sales and operating results could suffer
31% rewrittenRisks Related to Reliance on Third Parties and Business Continuity
We are dependent upon third-party suppliers, making us vulnerable to supply constraints and price fluctuations, and we may not be able to obtain sufficient components or raw materials on a timely basis or at all
Was: We are dependent upon third-party suppliers, making us vulnerable to supply problems and price fluctuations, and we may not be able to obtain sufficient components or raw materials on a timely basis or at all
29% rewrittenRisks Related to Information Technology (“IT”), Privacy and Security
Failure to maintain the privacy and security of our customer, third-party payor, employee, supplier, or Company information could result in substantial costs and/or subject us to litigation, enforcement actions, and reputational damage
28% rewrittenRisks Related to Reliance on Third Parties and Business Continuity
We rely on agreements or licenses to intellectual property or other rights in order to sell our current product and commercialize new products
28% rewrittenRisks Related to our Intellectual Property
Claims that our current or future products infringe or misappropriate the proprietary rights of others could adversely affect our ability to sell those products and cause us to incur additional costs
28% rewrittenRisks Related to Government Regulation and Product Liability
The occurrence of any of these events may have a material adverse effect on our business, financial condition, and results of operations
26% rewrittenGeneral Risks
Acquisitions or investments in new businesses, products, or technologies could disrupt our business
21% rewrittenRisks Related to Competition and Product Development
Technological breakthroughs in diabetes monitoring, treatment, or prevention could render our Omnipod products obsolete or less desirable

All 36 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Business

01We currently rely on sales of our Omnipod product platform to generate most of our revenue90% rewritten
02Our ability to grow our revenue depends in part on our retaining a high percentage of our customers64% rewritten
03If we do not effectively manage our rapid growth, our business resources may become strained and we may not be able to deliver our products in a timely manner, which could adversely affect our results of operations78% rewritten
04Failure to secure or retain adequate coverage or reimbursement for our products by third-party payors could adversely affect our business, revenue, financial condition, and results of operations56% rewritten
05If we fail to expand our relationships with intermediaries, our ability to grow our business may be materially and adversely affectedNew
06Our non-insulin Drug Delivery product line faces challenges which, if not met, may impair its future success37% rewritten

Risks Related to Competition and Product Development

07Our failure to compete effectively would negatively impact our revenue and results of operations83% rewritten
08Our new product development initiatives may prove to be ineffective or not commercially successful93% rewritten
09Technological breakthroughs in diabetes monitoring, treatment, or prevention could render our Omnipod products obsolete or less desirable21% rewritten
10Future market or clinical studies may be unfavorable to our Omnipod products and their efficacy, which could hinder our sales efforts and have a material adverse effect on our business, results of operations, financial condition, and cash flows47% rewritten

Risks Related to our Intellectual Property

11We may be unable to adequately protect our intellectual property rights, which could limit our ability to sell our products profitably, or at all, and cause us to incur additional costsNew
12Claims that our current or future products infringe or misappropriate the proprietary rights of others could adversely affect our ability to sell those products and cause us to incur additional costs28% rewritten

Risks Related to Economic Conditions and Operating Internationally

13The continuing worldwide macroeconomic and geopolitical uncertainty as well as the impact of another global pandemic may adversely affect our business and prospects56% rewritten
14The international nature of our business subjects us to additional business risks that may have an adverse effect on our financial condition or results of operationsNew
15Expansion of U.S. tariffs could have a material adverse effect on our financial resultsNew

Risks Related to Reliance on Third Parties and Business Continuity

16We rely on agreements or licenses to intellectual property or other rights in order to sell our current product and commercialize new products28% rewritten
17Our inventory is produced and maintained in a limited number of locations, including one operated by a third party in China, and any loss could have a material adverse effect on our ability to manufacture and sell our productsNew
18We are dependent upon third-party suppliers, making us vulnerable to supply constraints and price fluctuations, and we may not be able to obtain sufficient components or raw materials on a timely basis or at all31% rewritten
19Our manufacturing process is highly complex and subject to regulation; as demand for our products increase, we may experience manufacturing difficulties, including not effectively managing the start-up of new manufacturing lines or issues with our third-party contract manufacturer, which could harm our business55% rewritten
20If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval or commercialize our products

Risks Related to Government Regulation and Product Liability

21Healthcare reform laws could adversely affect our revenue and financial condition
22We are subject to extensive government regulation, which could restrict the sales and marketing of our products, cause us to incur significant costs, and impact our profitability and competitiveness
23The occurrence of any of these events may have a material adverse effect on our business, financial condition, and results of operations28% rewritten
24If we or our contract manufacturer fail to comply with the FDA’s quality system regulations, the manufacturing and distribution of our devices could be interrupted, and our sales and operating results could suffer33% rewritten
25Malfunction of our products could lead to recalls, safety alerts, or litigation and result in substantial costs and reputational damage
26We may be subject to enforcement action if we engage in improper marketing or promotion of our products
27If we fail to comply with fraud and abuse and other healthcare regulations, including those relating to Medicare and Medicaid, we could be subject to substantial penalties and/or be excluded from participation in government programs
28Failure to comply with the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws could materially adversely affect our business and result in civil and/or criminal sanctions

Risks Related to Information Technology (“IT”), Privacy and Security

29We rely on the proper function, availability, and security of our products and IT systems; a successful cyber-attack or other breach or disruption of our products or these systems could have a material adverse effect on our business and results of operations36% rewritten
30Failure to maintain the privacy and security of our customer, third-party payor, employee, supplier, or Company information could result in substantial costs and/or subject us to litigation, enforcement actions, and reputational damage29% rewritten

Risks Related to Debt

31Our Credit Agreement imposes restrictions on us that may adversely affect our ability to operate or grow our business
32We may need to raise additional funds in the future, and these funds may not be available on acceptable terms or at all

General Risks

33Our success depends on our ability to attract, motivate, and retain key personnel57% rewritten
34Acquisitions or investments in new businesses, products, or technologies could disrupt our business26% rewritten
35The price of our common stock may be volatile
36Changes in tax laws or exposures to additional tax liabilities could negatively impact our operating results

Other Insulet 10-Ks

FY2024 10-K risk factors
40 risks
Nearly all revenue depends on the Omnipod platform and its pharmacy channel distribution. Manufacturing relies heavily on a new Malaysian facility, a US site, and a Chinese contractor. Substantially all Drug Delivery revenue relies on Amgen's Neulasta Onpro kit agreement expiring in December 2028.
Filed Feb 21, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.